ASH Summit on Immunotherapies for Hematologic Diseases
March 2-3, 2023
Omni Shoreham Hotel, Washington, DC
Why is the success of immunotherapies and other targeted therapies such as gene therapy so variable within different patient populations? How can we improve these targeted therapies for widespread use in patients with hematologic diseases? Help answer these questions and more at the ASH Summit on Immunotherapies for Hematologic Diseases.
This in-person Summit is a unique meeting of the minds, bringing together academic, medical, industry, and federal regulatory communities to address the obstacles in immunotherapy treatment development for classical and malignant hematologic conditions. Whether you’re an established academic investigator, trainee, practicing clinician, industry researcher, or federal regulator, you won’t want to miss this unique opportunity to share ideas! Through participation in this meeting, attendees will be able to:
- Discuss fundamental advances in basic immunology that provide the foundation for immune therapies and their application
- Gain insights into critical limitations of immunotherapies and gene therapy including associated adverse events
- Examine cellular and molecular mechanisms involved in resistance and relapse associated with these therapies
- Review new immunotherapy targets
- Discuss the application of CRISPR gene editing in the development of targeted therapies
- Analyze cell manufacturing considerations
- Learn about the application of immunotherapies for the treatment of both classical hematologic and malignant diseases
Target Audience
The ASH Summit on Immunotherapies for Hematologic Diseases is designed to provide a wide set of learning and networking opportunities for experts in hematology, including:
- Laboratory-based scientists
- Translational and clinical researchers
- Practitioners interested in the application of immunotherapies
- Young investigators (trainees)
- Cellular therapy, gene therapy, biopharmaceutical, and life sciences industry experts
- Regulatory scientists
Summit Abstracts
Full abstract text will be available to registered attendees via the mobile app. In accordance with the event’s embargo guidelines, for poster presentations, the embargo lifts when the poster hall containing the poster opens for viewing and for oral/invited presentations, the embargo lifts at the start time of the session in which the presentation is being made.
| Abstract # | Title | Presenter | Presentation |
| 1 | HMGA1 Chromatin Regulators Drive Immune Evasion in MPN Progression through Epigenetic Rewiring to Repress Networks Involved in Antigen Presentation | Joseph Kim | Oral |
| 2 | Safety and Anti-Leukemic Activity of CD123-CAR T Cells in Pediatric Patients with AML: Preliminary Results from a Phase 1 Trial | Swati Naik | Oral |
| 3 | Tgfß-Imprinting of Primary NK Cells Decreases CD38-Nadase, Promotes a Tissue-Resident Addressin Profile, and Improves Cytotoxicity and Metabolism | Marcelo Pereira | Oral |
| 4 | Rhoa Inactivation As a Driver of CAR-T Therapy Resistance in Diffuse Large B-Cell Lymphoma | Austin D. Newsam | Oral |
| 5 | Tunable Activation of CD19-CART Results in Enhanced Metabolic Activity and Cytotoxicity Against Antigen-Low Leukemia | Mehdi Benzaoui | Oral |
| 6 | Evaluation of CD38KO/CD38-CAR Human Primary Natural Killer Cells Against CD38-Expressing Hematologic Malignancies | Ella C. Troy | Oral |
| LBA - 1 | Cord Blood-Derived CD19-Specific Chimeric Antigen Receptor T Cells: An Off-the-Shelf Promising Therapeutic Option for Treatment of Diffuse Large B-Cell Lymphoma | Tiantian Yu | Oral |
| 7 | Deletion of AMPK Reduces Oxidative Metabolism in Gvhd-Causing Human T Cells | Archana Ramgopal | Poster & Rapid Fire Talk |
| 8 | Novel Therapeutic Strategies to Overcome Hyperthermia-Induced Metabolic Dysfunction of CAR-T Cells | Taisuke Kondo | Poster & Rapid Fire Talk |
| 9 | Use of a Foamy-Virus Vector System to Produce an ‘Off-the-Shelf’ Fcγ-CR-T Cell Product for the Treatment of Hematological and Solid Tumor Malignancies | Ioanna Lazana | Poster & Rapid Fire Talk |
| 10 | Multiple Myeloma & Severe Sars-Cov-2: Delving into the Immunological Paradigm with a Promising Cellular Therapeutic Intervention | Yan Leyfman | Poster |
| 11 | The Roles and Challenges of Advanced Therapies in the Management of Refractory Immune Thrombocytopenia: A Case Report and Review of Literature | Beatrice Torere | Poster |
| 12 | Correlations between Overall Response Rate, Progression-Free Survival and Overall Survival with Belantamab Mafodotin in Refractory or Relapsed Multiple Myeloma | Nosakhare Ilerhunmwuwa | Poster |
| 13 | A Retrospective Study of Clinical Outcomes in Patients with Non-Hodgkin Lymphoma with Secondary Central Nervous System Involvement after CD19 CAR-T Therapy | Aseel Alsouqi | Poster & Rapid Fire Talk |
| 14 | Longitudinal Geriatric Assessment in Older Patients with Relapsed Refractory, Large B-Cell Lymphoma Receiving CAR T-Cell Therapy: A Prospective Pilot Study | Richard Lin | Poster & Rapid Fire Talk |
| 15 | Hemophagocytic Lymphohistiocytosis As a Complication of CAR-T Cell Therapy: A Case Report | Flavia Gava | Poster |
| 16 | Outcomes of Myeloid Sarcoma: A 10-Year Institutional Study | Kriti Gera | Poster |
| 17 | Visualizing CAR-T Cell Trafficking Using the NIS Reporter | Brynn Duncan | Poster & Rapid Fire Talk |
| 18 | Bridging the Gap of Healthcare Access: Utilizing an Ontology Platform to Connect BALT Patients with COVID-19 to Active Immunotherapeutic Clinical Trials | Yan Leyfman | Poster |
| 19 | Viral Escape in Cytomegalovirus Viral-Specific T Cell Therapy Resistance | John Idso | Poster |
| LBA-2 | The CLEC2D/CD161 Axis As a Novel Ligand/Receptor Pathway for Immunotherapeutic Intervention in CLEC2D+Hematological Malignancies | Shruti Malu | Poster |
Abstract Winners
| Joseph Kim Johns Hopkins University School of Medicine |
HMGA1 Chromatin Regulators Drive Immune Evasion in MPN Progression through Epigenetic Rewiring to Repress Networks Involved in Antigen Presentation |
|
Brynn B. Duncan, MD |
Visualizing CAR-T Cell Trafficking Using the NIS Reporter |
| Austin D. Newsam, BS University of Miami Miller School of Medicine |
Rhoa Inactivation As a Driver of CAR-T Therapy Resistance in Diffuse Large B-Cell Lymphoma |
| Taisuke Kondo, PhD National Institutes of Health |
Novel Therapeutic Strategies to Overcome Hyperthermia-Induced Metabolic Dysfunction of CAR-T Cells |
| Aseel Alsouqi, MD University of Pittsburgh Medical Center |
A Retrospective Study of Clinical Outcomes in Patients with Non-Hodgkin Lymphoma with Secondary Central Nervous System Involvement after CD19 CAR-T Therapy |
Program Schedule
| 7:00 a.m. Hampton Ballroom |
Breakfast/Exhibits Open |
|
8:15 a.m. |
Keynote Address Chair: Speaker: |
|
9:00 a.m. |
The Science of Immunotherapy Chairs: Antonio Risitano, MD, PhD Madhav Dhodapkar, MBBS Speakers: Personalized Immune Based Strategies in Cancer The Future of Science of Cancer Immunotherapy Uncertain Mechanisms of Action of Successful Biologics - ATG Focus |
|
10:55 a.m. |
Use of Immunotherapies in Clinical Practice or Trials Chairs: Katy Rezvani, MD Sarah Cooley, MD Speakers: Chimeric Antigen Receptor (CAR) Engineering Beyond T-Cells T-Cell Engineering Beyond CAR |
| 12:00 p.m. Hampton Ballroom |
Lunch/Exhibits Open |
|
1:00 p.m. |
Use of Immunotherapies in Clinical Practice or Trials (Continued) Chairs: Sarah Cooley, MD Speakers: Bispecific Antibodies in Hemophilia Presentation from the Chinese Society of Hematology: BCMA CART in China and Beyond |
|
2:30 p.m. |
Mechanisms of Resistance to Immunotherapies Chairs: Rodrigo Calado, MD, PhD Loretta Nastoupil, MD Speakers: Initial Treatment Failure Relapse Associated with Late Immunotherapy Failure Targeting Innate Immunity: Anti-Complement Therapies |
|
4:55 p.m. |
Cell Manufacturing Considerations: Transitioning from Early to Late Phase Trials to Licensure Chairs: Catherine Bollard, MD, MBChB Terry Fry, MD Academia Perspective: Challenges in the Academia Setting to Take Novel Platforms into the Clinic - How Have They Approached IND Filings (gene editing) Industry Perspective: Challenges in the Industry Setting; Dealing with Adverse Events (from a GMP Perspective) The Regulatory Perspective: Cell Manufacturing Considerations Tunable Activation of CD19-CART Results in Enhanced Metabolic Activity and Cytotoxicity Against Antigen-Low Leukemia |
| 6:40 p.m. Blue Pre-Function Room |
Welcome Reception and Poster Presentations |
|
8:00 a.m. |
Breakfast/Exhibits Open |
|
9:00 a.m. |
Emerging Strategies to Overcome Current Immunotherapy Limitations Chairs: David Scott, PhD Frederick Locke, MD Speakers: Emicizumab and ITI: Partners or Foes Improving CAR T By Promoting Intracellular and Extracellular Signaling Genome Editing for Adoptive T Cell Therapy |
|
11:00 a.m. |
Poster Presentations |
|
12:00 p.m. |
Lunch/Exhibits |
|
1:00 p.m. |
Immunotherapy Toxicities – Prediction and Management Chairs: Jae Park, MD Rayne Rouce, MD Speakers: Cytokine Release Syndrome Neurotoxicity Off-Target Effects of Immunotherapy |
|
2:55 p.m. |
Late Breaking Special Session (ASH-SITC JOINT Session) Chairs: John Tisdale, MD Nina Shah, MD Speakers: The Immune Predictors of Response to CAR T and Bispecific T Cell Therapy Novel Technologies to Improve and Safely Deliver Gene Therapies Cord Blood-Derived CD19-Specific Chimeric Antigen Receptor T Cells: An Off-the-Shelf Promising Therapeutic Option for Treatment of Diffuse Large B-Cell Lymphoma |
View the Schedule at-a-Glance for additional details on the Summit’s program.
2023 Program Co-Chairs
- Shannon Maude, MD, PhD, Children’s Hospital of Philadelphia
- Terry Fry, MD, University of Colorado School of Medicine and Sana Biotechnology
- Neal Young, MD, National Institutes of Health
ASH Summit Steering Committee
- Catherine Bollard, MD, Children’s National Medical Center
- Rodrigo Calado, MD, PhD, University of Sao Paulo
- Sarah Cooley, MD, MS, Fate Therapeutics
- Madhav Dhodapkar, MD, Emory University
- Stephen Forman, MD, City of Hope
- Frederick Locke, MD, Moffitt Cancer Center
- Loretta Nastoupil, MD, MD Anderson Cancer Center
- Jae Park, MD, Memorial Sloan Kettering Cancer Center
- Katy Rezvani, MD, PhD, Anderson Cancer Center
- Antonio Risitano, MD, PhD, University of Naples
- David Scott, MS, PhD, Uniformed Services University of Health Sciences
- Guy Young, MD, Children’s Hospital of Los Angeles
Questions?
For questions about the program for the 2023 ASH Summit on Immunotherapies for Hematologic Diseases, please contact ASH Deputy Director of Scientific Affairs Alice Kuaban at [email protected].
For general inquiries about this meeting, please submit them to [email protected].
Help ASH Build an Inclusive Hematology Community!
ASH is committed to building and nurturing a global hematology community and workforce inclusive of diverse perspectives, talents, and experiences as it works toward one collective goal: helping hematologists conquer blood diseases worldwide.
How Can You Help?
Visit your My Account page, make needed updates to your demographic details, and select your preferred level of ASH access to your information; aggregated or individually identifiable, or choose not to provide or share your information. By sharing information about who you are, you will help ASH have a better appreciation of the diverse needs and talents present in the field, and help to build a more inclusive, collaborative hematology community. It will take only a few moments to complete!
Update Access to Demographic Information Learn About Our Mission